Metoclopramide Accord

Metoclopramide, the active ingredient in Metoclopramide Accord, is a dopamine antagonist presented as an oral tablet for oral use. It treats nausea, vomiting and related gastrointestinal motility disorders in adults.

GNH USA supplies Metoclopramide Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide is used to manage conditions that involve impaired gastrointestinal motility or nausea pathways.

- Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone. - Gastroparesis: enhances gastric emptying and improves digestive symptoms. - Gastro‑oesophageal reflux disease: increases lower‑esophageal sphincter tone and promotes gastric clearance. - Migraine‑associated nausea: provides antiemetic relief during migraine attacks.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness or fatigue - Restlessness or agitation - Diarrhea or abdominal cramping - Headache - Insomnia - Dry mouth

Serious or Rare Side Effects: - Tardive dyskinesia (involuntary movements) - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Seizures - Anaphylactic or severe allergic reactions - Cardiac arrhythmias

Before prescribing Metoclopramide, consider patient‑specific factors and safety measures.

- Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly: increased sensitivity to central nervous system effects; monitor closely. - Renal impairment: dose adjustment may be required due to reduced clearance. - History of movement disorders: avoid because of heightened risk of extrapyramidal symptoms. - Concomitant medications: review for potential interactions that may amplify adverse effects. - Store at room temperature: keep in the original container, protect from moisture and light.

Metoclopramide can interact with several drug classes; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Anticholinergic agents: may increase anticholinergic burden and reduce efficacy. - CYP2D6 inhibitors (e.g., quinidine, fluoxetine): can raise metoclopramide plasma concentrations. - Other dopamine antagonists: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: risk of serotonin syndrome when combined. - Other antiemetics (e.g., ondansetron): may cause excessive antiemetic effect. - Alcohol: enhances central nervous system depression and sedation.